BNTX — BioNTech SE Cashflow Statement
0.000.00%
Last trade - 00:00
- $21.83bn
- $4.19bn
- €3.82bn
- 92
- 78
- 20
- 68
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 20-F | 20-F | 20-F | 20-F | 20-F |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -179 | -146 | 15,046 | 12,954 | 1,186 |
Depreciation | |||||
Non-Cash Items | 31.1 | 188 | -32.6 | 248 | -577 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -84.1 | -94.9 | -14,199 | 252 | 4,579 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Accounts Payable | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -199 | -13.5 | 890 | 13,577 | 5,371 |
Capital Expenditures | -71.1 | -85.4 | -154 | -363 | -706 |
Purchase of Fixed Assets | |||||
Purchase / Acquisition of Intangibles | |||||
Other Investing Cash Flow Items | -6.04 | -59.4 | -412 | 328 | -6,249 |
Acquisition of Business | |||||
Sale of Business | |||||
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -77.1 | -145 | -566 | -35.3 | -6,955 |
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 383 | 895 | 94.2 | -1,419 | -779 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 108 | 691 | 483 | 12,182 | -2,211 |